Were Analysts Bullish Epizyme, Inc. (NASDAQ:EPZM) This Week?

Epizyme, Inc. (NASDAQ:EPZM) Logo
Investors sentiment increased to 2.34 in Q2 2019. Its up 0.60, from 1.74 in 2019Q1. It increased, as 16 investors sold Epizyme, Inc. shares while 19 reduced holdings. 32 funds opened positions while 50 raised stakes. 80.53 million shares or 8.06% more from 74.53 million shares in 2019Q1 were reported.
Fred Alger Management Inc holds 57,000 shares or 0% of its portfolio. Ghost Tree Capital Lc reported 465,000 shares or 1.22% of all its holdings. Bankshares Of America De holds 110,195 shares. Parkside Bancorp reported 1,062 shares. Aperio Group reported 0% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM). Exane Derivatives stated it has 6,800 shares or 0% of all its holdings. Northern Tru Corp invested in 0% or 796,239 shares. Barclays Plc holds 50,563 shares or 0% of its portfolio. Ameriprise has 116,300 shares. Invesco Ltd holds 17,141 shares. 193,672 are owned by Products Partners Lc. State Of Wisconsin Inv Board, a Wisconsin-based fund reported 86,500 shares. Consonance Capital Management L P holds 4.23% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM) for 4.76 million shares. Redmile Grp Inc Lc stated it has 8.73M shares or 3.1% of all its holdings. Metropolitan Life New York has invested 0% in Epizyme, Inc. (NASDAQ:EPZM).

Epizyme, Inc. (NASDAQ:EPZM) Ratings Coverage

Among 2 analysts covering Epizyme (NASDAQ:EPZM), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Epizyme has $25 highest and $18 lowest target. $21.50’s average target is 79.77% above currents $11.96 stock price. Epizyme had 3 analyst reports since June 1, 2019 according to SRatingsIntel. Cowen & Co maintained the stock with “Buy” rating in Friday, June 21 report. The firm earned “Buy” rating on Monday, June 24 by H.C. Wainwright. Below is a list of Epizyme, Inc. (NASDAQ:EPZM) latest ratings and price target changes.

24/06/2019 Broker: H.C. Wainwright Rating: Buy New Target: $25 Maintain
21/06/2019 Broker: Cowen & Co Rating: Buy New Target: $18 Maintain
01/06/2019 Broker: BidaskScore Rating: Buy Upgrade

The stock decreased 1.48% or $0.18 during the last trading session, reaching $11.96. About 1.69 million shares traded or 119.20% up from the average. Epizyme, Inc. (NASDAQ:EPZM) has risen 7.80% since September 13, 2018 and is uptrending. It has outperformed by 7.80% the S&P500.

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States. The company has market cap of $1.09 billion. The Company’s product candidates include tazemetostat, an inhibitor of the EZH2 HMT, which is in five-arm Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma ; Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II and Ib clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial for elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function, as well as Phase II clinical trial in adult patients with ovarian cancer. It currently has negative earnings. The firm is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL.

More notable recent Epizyme, Inc. (NASDAQ:EPZM) news were published by: Nasdaq.com which released: “Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat – Nasdaq” on August 15, 2019, also Finance.Yahoo.com with their article: “How Should Investors Feel About Epizyme, Inc.’s (NASDAQ:EPZM) CEO Pay? – Yahoo Finance” published on August 16, 2019, Seekingalpha.com published: “Epizyme launches equity offering – Seeking Alpha” on March 06, 2019. More interesting news about Epizyme, Inc. (NASDAQ:EPZM) were released by: Nasdaq.com and their article: “Where Will Epizyme Be in 1 Year? – Nasdaq” published on September 05, 2019 as well as Nasdaq.com‘s news article titled: “Epizyme (EPZM) Shares Surge More Than 100% YTD: Here’s Why? – Nasdaq” with publication date: May 28, 2019.

Epizyme, Inc. (NASDAQ:EPZM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.